A first-in-class intravenous kappa opioid receptor (KOR) agonist, an oral soluble guanylate cyclase (sGC) stimulator, a first-in-class subcutaneous complement C3 inhibitor, and an oral contraceptive comprising a synthetic progesterone (drospirenone) and a plant-based estrogen (estetrol) make up the final group of novel drugs from 2021 that we didn’t cover in our other indication-specific reviews. In 2021, the FDA approved four new drugs for various other indications, from rare diseases to pregnancy prevention.
This article and slide deck explores each in more detail, including but not limited to their:
- mechanisms of action
- target rationale
- disease context
- original patents
- key clinical data
- industry history
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:
